E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Decreased bone mineral density in prostate cancer patients being treated with ADT |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare the effect of intravenous Zometa® (zoledronic acid) 4 mg administered every 12 weeks (arm 1) versus every 24 weeks (arm 2) on bone loss associated with initial ADT (LHRH agonist or orchidectomy) in men with stage MO (no distant metastases) prostate carcinoma.
This will be evaluated by measuring the percent change in bone mineral density (BMD) of the lumbar spine, specifically L2-L4, by dual energy x-ray absorptiometry (DXA).
|
|
E.2.2 | Secondary objectives of the trial |
-To compare the effect of Zometa® 4 mg every 12 versus 24 weeks on the percent change in BMD of : - the total hip following one year of therapy. - the forearm following one year of therapy. This will be carried out at a limited number of centres. -To compare the effect of Zometa® 4 mg every 12 versus 24 weeks on quality of life following one year of therapy. -To compare the effect of Zometa® 4 mg every 12 versus 24 weeks on various biochemical markers of bone resorption (N-telopeptide, NTX, C-telopeptide, CTX, TRACP, PINP) and bone formation (bone alkaline phosphatase, BAP) during one year of therapy. This will be carried out at a limited number of centres. -To compare the safety and tolerability of Zometa® 4 mg every 12 versus 24 weeks. -To compare the effect of Zometa® 4 mg every 12 versus 24 weeks on time to, percentage of and rate of vertebral and hip fractures.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed informed consent • Age > 18 years • Histologically confirmed diagnosis of carcinoma of the prostate • No distant metastases (stage Tany Nany MO) • Patients must be candidates for the initiation of androgen deprivation therapy (ADT) • Patient with a baseline BMD T-score at or below -1 standard deviations in the lumbar spine (L2-L4) are eligible • Life expectancy of at least 12 months • ECOG performance status of 0, 1, or 2
|
|
E.4 | Principal exclusion criteria |
• Patients with normal BMD at trial entry • Patients who received any prior bisphosphonate therapy in the past 12 months • Patients who have received previous treatment with LHRH agonists or have undergone an orchidectomy more than 1 month before visit 1. • Treatment with anti-androgen mono- or combination therapy. (However, patients can receive a maximum of 6 weeks total anti-androgen therapy to control flare). • Patients who are currently receiving diethylstilbesterol (DES) or who have previously received PC-SPES • Patients who have received prior treatment with systemic corticosteroids within the past 12 months (short term corticosteroid therapy, e.g. to prevent/treat chemotherapy-induced nausea/vomiting or for acute illness like asthma exacerbation, is acceptable) • Patients with prior exposure to anabolic steroids or growth hormone within the past 6 months • Patients with any prior treatment for osteoporosis • Patients with previous or concomitant malignancy within the past 5 years except adequately treated basal or squamous cell carcinoma of the skin, and colonic polyps with non-invasive malignancy which have been removed • Patients with nonmalignant conditions which would confound the evaluation of the primary endpoint, impair tolerance of therapy, or prevent compliance to the protocol, including: -uncontrolled infections -uncontrolled type 2 diabetes mellitus -diseases with influence on bone metabolism, such as Paget’s disease or uncontrolled thyroid or parathyroid dysfunction -cardiovascular, renal, hepatic, pulmonary and neurologic/psychiatric diseases which would prevent prolonged follow-up • History of surgery at the lumbosacral spine, with or without implantable devices, bilateral hip replacement or bilateral hip surgery with implantation of an appliance. . Any condition that prevents the patients from having a DEXA scan (eg deformities of the spine). • Patients treated with systemic investigational drugs(s) and /or device(s) within the past 30 days • Abnormal renal function as evidenced by a calculated creatinine clearance <30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula • Current active dental problems including infection of the teeth or jawbone (maxilla or mandible); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. • Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants) • Known hypersensitivity to Zometa® (zoledronic acid) or other bisphosphonates • Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study • Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer • History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The percentage change in bone mineral density (BMD) of the lumbar spine, specifically L2-L4 by dual energy x ray absorptiometry (DXA) at a 12 month timepoint. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |